Mosaic ImmunoEngineering is a nanotechnology-based immunotherapy company developing therapeutics and vaccines to positively impact the lives of patients and their families.

Free
Message: All very interesting...

This was and Edgar alert today...

Are there this many shares still outstanding or did all this 1:70,000 share garbage take place already and they are now just filing?

Here it is:

"As described above, the Reporting Person holds 70,000 shares of Series B Preferred Stock, and each share of the Series B Preferred may be converted into 5,734.185 shares of Common Stock of the Issuer upon the events described in Item 3, above. All such shares are beneficially owned by the Reporting Person and the Reporting Person has the sole power to vote and dispose of such shares.

Based on the foregoing, as of November 30, 2020, the Reporting Person may be deemed to beneficially own 401,392,950 shares of the Common Stock, which represents approximately 50% of the shares of the Common Stock issued and outstanding (as of October 22, 2020). When taking into account the conversion of the Series A Preferred Stock held by other persons, the Reporting Person’s beneficial ownership of the Common Stock underlying the Series B Preferred Stock represents approximately 10% of the Issuer’s Common Stock."

 

Share
New Message
Please login to post a reply